Caldera Therapeutics
↗Cambridge, USA
Caldera Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class bispecific antibody therapeutics for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The company aims to redefine the efficacy ceiling in IBD by targeting multiple validated pathways simultaneously.
The company's lead program, CLD-423, is a bispecific antibody that targets both the IL-23p19 and TL1A pathways. Caldera was launched with significant backing from top-tier biotech investors and is led by a management team with a proven track record in the IBD space, including former leadership from Morphic Therapeutic.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$112.5M
Investors:Atlas Venture, LAV, venBio, Omega Funds, Wellington Management, Janus Henderson Investors
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Bispecific antibody
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Qyuns Therapeutics (Exclusive global license for CLD-423)
COMPETITION
Position:Emerging
Competitors:Boehringer Ingelheim, Simcere Pharmaceutical, Novamab, Episcience, Roche (Telavant), Sanofi/Teva
LEADERSHIP
Key Executives:
Praveen Tipirneni, MD - CEO
Liangsu Wang, PhD - CSO
Zhong Liu - CTO
Scientific Founders:Praveen Tipirneni, Atlas Venture (Incubator)
Board Members:Michelle Doig (Omega Funds)
LINKS
Website:calderatx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Caldera Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.